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Objective: Our intent was to refine the patient selection criteria for lung 
volume reduction surgery because various centers have different criteria 
and not all patients benefit from the procedure. Methods: Patient informa 1
tion, x-ray results, arterial blood gases, and plethysmographic pulmonary 
function tests in 154 consecutive patients who underwent bilateral thora- 
coscopic staple lung voIume reduction surgery were compared with clinical 
outcome (change in forced expiratory volume in 1 second and dyspnea 
scale) with t tests and analysis of variance. Results: Three hundred 
thirty-three of 487 (69%) patients evaluated for lung volume reduction 
surgery were rejected for lack of heterogeneous emphysema (n = 212), 
medical contraindications (n = 88), hypercapnia (n = 20), uncontrolled 
anxiety or depression (n = 10), or pulmonary hypertension (n -- 1). Two 
patients died during the evaluation process. When tested by analysis of 
variance, there was no difference in clinical outcome associated with 
preoperative forced expiratory volume in 1 second, residual volume, total 
lung capacity, single-breath diffusing, and arterial oxygen or carbon dioxide 
tension. All patients elected for the operation had a heterogeneous pattern 
of emphysema. The upper lobe heterogeneous pattern of emphysema on 
chest computed tomography and lung perfusion scan was strongly associ- 
ated with improved outcome with a mean (95% confidence interval) 
improvement in forced expiratory volume in 1 second of 73.2% (63.3 to 83.1) 
for the upper lobe compared with a mean (95% confidence interval) 
improvement of 37.9% (22.9 to 53.0) for the lower lobe or diffuse pattern of 
emphysema. Conclusion: The most important selection criteria for lung 
volume reduction surgery is the presence of a bilateral upper lobe hetero- 
geneous pattern of emphysema on chest computed tomography and lung 
perfusion scan. After patients have been selected on the basis of a 
heterogeneous pattern of emphysema, clinical factors and physiology are 
not associated with clinical outcome well enough to further refine patient 
selection criteria. These results do not support the arbitrary patient 
selection criteria for lung volume reduction surgery reported in the 
literature. (J Thorac Cardiovasc Surg 1997;114:957-67) 
W hen Cooper and associates 1 reported an 82% improvement in forced expiratory volume in 1 
second (FEVi)  after lung volume reduction surgery 
(LVRS), they created tremendous interest in this 
procedure, because no previous treatment (aside 
from lung transplantation) had been shown to im- 
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prove pulmonary function for persons who were 
severely disabled by emphysema. Results from other 
authors have confirmed that LVRS produces ignif- 
icant improvement in pulmonary function, freedom 
from supplementary oxygen, and quality of life. a-l° 
There were many questions regarding the optimal 
surgical technique, mechanisms of improvement, 
and patient selection for LVRS when Cooper's 
group 1 reported on their first 20 patients. In a 
randomized prospective study, we 9 showed that the 
staple technique produced a greater improvement in 
FEV 1 (33% vs 13%) and quality of life than the laser 
technique. Bilateral staple LVRS resulted in greater 
freedom from supplementary oxygen (68% vs 35%), 
prednisone independence (86% vs 56%), and im- 
provement in pulmonary function (57% vs 35%) 
than unilateral staple LVRS. ~° The mechanism of 
improvement is a significant improvement in lung 
elastic recoil and compliance without any change in 
chest wall compliance. 
The reported series of LVRS have recommended 
sPecific patient selection criteria regarding age, hy- 
percarbia, prednisone use, oxygen use, diaphrag- 
matic excursion, plethysmographic results, and the 
radiologic pattern o f  emphysema. In these series, 
there is considerable variation in patient selection 
criteria and little or no objective data to support he 
establishment of these criteria. Recent editorials call 
for better definition of patient selection. TM 12 
AI! patients in this series have a heterogeneous 
pattern of emphysema. Our follow-up has shown 
that the condition Of a high percentage of our 
patients is significantly improved, but that a minority 
of patients have 0nly mild improvement and some 
have no improvement at all. This review was there- 
fore undertaken to specifically analyze our results 
after bilateral staple LVRS to further refine the 
selection criteria when LVRS is performed for 
patients with a heterogeneous pattern of emphysema. 
Patients and methods 
Between May 1995 and May 1996, 154 patients under- 
went bilateral staple LVRS at Chapman Medical Center 
with a previously described video-assisted thoracic surgery 
technique.9. 10 ~l;1]is included 98 men and 56 women with a 
mean age of 67.1 _+ 6.8 years (range 45 to 79 years). 
These cases were analyzed to evaluate the potential 
selection criteria for LVRS. Routine preoperative evalu- 
ation included history and physical examination, arterial 
blood gases with the patient breathing room air, chest 
roentgenogram, chest computed tomographic (CT) scan, 
lung perfusion scan, and pulmonary function tests by 
helium dilution and plethysmography. 
Entry criteria for selection in this series have been 
previously described. 9' 10 Despite maximal medical man- 
agement, all patients had marked symptoms, as measured 
by dyspnea index 13 and quality of life assessment. TM Chest 
roentgenograms showed hyperexpansion f the thorax 
with flattening or inversion of the diaphragm. 
Contraindications to surgery included current cigarette 
smoking, age older than 80 years, severe cardiac disease, 
history of cancer within the past 5 years, ventilator depen- 
dency, or prior thoracic surgery. Relative contraindica- 
tions included age older than 75 years, severe anxiety, 
severe depression, or severe carbon dioxide retention 
(arterial carbon dioxide tension [Paco2] > 55 mm Hg). 
To be accepted for the procedure, patients had to have 
a pattern of emphysema on CT that was heterogeneous and 
graded as severe. 15 The CT scan pattern was classified as 
upper lobe if the emphysema was primarily in the upper 
lobes, lower lobe if concentrated in the lower lobes, and 
diffuse if there was a heterogeneous pattern of emphysema 
with discrete areas of severe mphysema present in both 
upper and lower lobes. Radionuclide lung perfusion scans 
were als0 used to confirm the heterogeneous pattern of 
emphysema. 
All patients underwent room air arterial blood gas 
analysis and lung function studies that included static lung 
volumes measured by plethysmographic techniques, 16
timed spirometry and single-breath diffusing Capacity 
(DLCO) in accordance with American Thoracic Society 
recommendations,17, la and values were compared with 
predictions. 19-21 All patients were considered to have fixed 
airflow limitation since the FEV 1 after three inhalations of 
aerosolized albnterol (INN: salbutamol) (670 txg) im- 
proved less than 12% and/or less than 200 ml. is The best 
post-bronchodilator FEV 1 was used for preoperative and 
postoperative evaluation of the patients: Maximum in- 
spiratory and expiratory flow volume curves, thoracic gas 
volum@ 6 and airway resistance ~6 were measured in a 
plethysmograph (models 2800 and 6200, Sensormedics, 
Inc., Yorba Buena, Calif.) and compared with predicted 
values. 22 The reciprocal of airway resistance, 16conduc- 
tance, was divided by the thoracic gas volume at which it 
was measured to calculate specific conductance. Residual 
volume was Calculated by subtracting vital capacity from 
total lung capacity. Complete lung function studies were 
obtained before the operation. Generally, only timed 
spirometry and arterial blood gases were available after 
the operation. 
All patients were clinically assessed and followed up 
with the Medical Outcome Survey (MOS) 36-item short- 
form health survey23 and the Modified Medical Research 
Council (MMRC) dyspnea scale. 24 Pre0perative arterial 
blood gases for the patients who underwent the operation 
showed a mean (95% confidence interval [CI]) arterial 
oxygen tension (Pao2) of 65.41 mm Hg (63.26 to 67.56 mm 
Hg) and an arterial carbon dioxide tension (Paco2) of 
42.90 mm Hg (41.70 to 44.10 mm Hg). Preoperative 
pulmonary function tests showed a mean (95% CI) FEV~ 
of 0.64 L (0.61 to 0.69 L), a forced vital capacity of 2.01 L 
(1.89 to 2.13 L), a total ung capacity of 7.18 L (6.88 to 7.48 
L), a residual volume of 4.52 L (4.28 to 4.76 L), and a 
residual volume/total lung capacity of 0.66 (0.65 to 0.68). 
Most patients ha d undergone pulmonary rehabilitation, 
but it was not a preoperative r quirement. 
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Table I. Relationship between radiologic pattern of emphysema and clinical outcomes 
AFEV 1 (L) %AFEV 1 A %Pred ADyspnea 
Pattern Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% C1) 
Upper lobe 0.43 (0.37, 0.49) 73.18 (63.29, 83.06) 16.72 (14.60, 18.84) 1.63 (1.40, 1.86) 
Low/diffuse 0.22 (0.15, 0.30) 37.95 (22.92, 52.97) 8.43 (5.15, 11.70) 1.88 (1.40, 2.36) 
Significance* p = 0.0013 p = 0.0007 p - 0.0002 p = 0.34 
Pattern, Location of the areas of emphysema t rgeted for resection; Low~diffusion , patients with areas of emphysema in lower lobes or multiple lobes for 
resection; AFEV1, change from baseline FEV1 in liters; %AFEV1, percent change from baseline FEV 1 in liters; A%Pred, change from baseline percent 
predicted FEVa; ADyspnea, change in dyspnea score. 
*t Test for difference between two means. 
Clinical follow-up was available for all patients. There 
were seven deaths among the 154 patients (4.5%). Fol- 
low-up pulmonary function tests were available for 138 of 
147 (93.9%) surviving patients. The mean (95% CI) 
length of stay for all patients was 9.3 days (8.3 to 10.3 
days) and for patients with follow-up data it was 8.8 days 
(7.8 to 9.8 days, range 3 to 36 days). 
Statistical analysis. Associations between preoperative 
patient characteristics and clinical outcome were investi- 
gated with the use of t tests (for comparisons between two 
groups) and analysis of variance (ANOVA) (comparison 
of more than two groups). The measures of clinical 
outcome used in the analyses include change in FEV1, 
percent change from baseline FEV1, change in FEV1 
percent predicted, and change in dyspnea score. Indepen- 
dent or grouping variables included patient characteristics 
previously described as selection Criteria in published 
series of LVRS. Two-way ANOVA was used to investigate 
the independent effects of two independent variables and 
possible interactions between them. Analyses were con- 
ducted with the use of the BMDP statistical software 
package (BMDP Software, Los Angeles, Calif.). 
Cut points for continuous independent variables used in 
ANOVA models were chosen on the basis of biologic 
plausibility and prior research. Age was analyzed in 5-year 
groups (60 to 64, 65 to 69, 70 to 74, and 75+ years) to 
investigate the possibility of a nonlinear relationship 
between age and clinical outcome, Pairwise differences 
between groups were examined with the use of t tests with 
a Bonferroni adjustment for multiple comparisons. Be- 
cause the extreme age subgroups (youngest and oldest age 
groupings) included smaller numbers and did not differ 
significantly from adjacent subgroups, they were com- 
bined to form two age groups (<70 and 70+ years) for the 
ANOVA models presented. 
Results 
During the time period of this series, 333 of 487 
(69%) patients evaluated for LVRS were turned 
down for the following reasons: lack of heteroge- 
neous pattern of emphysema (n = 212), medical 
contraindications (n = 88), hypercapnia (n = 20), 
uncontrolled anxiety or depression (n = 10), or 
pulmonary hypertension (  = 1); two patients died 
while awaiting the operation. The percent of pa- 
tients chosen for LVRS was as high as 31% because 
some pulmonologists who regularly refer patients to 
this center prescreen their patients o that almost all 
of the patients that they refer meet our criteria for 
the procedure. Clinical follow-up data are available 
for all patients and pulmonary function data are 
available for 138 of 147 surviving patients. 
Roentgenographic pattern of emphysema. Clini- 
cal response to the operation was compared with the 
roentgenographic pattern of emphysema. The loca- 
tion of the emphysema targeted for resection was 
upper lobe in 106 (77%), lower lobe in 10 (7%), and 
diffuse in 22 (16%) of the patients. Clinical out- 
come, measured by all three variables assessing 
change in FEV1, was significantly better for upper 
lobe pattern than for other patterns (t test for 
difference between means, p < 0.001 for each 
outcome variable). Patients with upper lobe disease 
experienced a 73.2% improvement in FEV 1 from a 
preoperative mean of 0.64.(95% CI, 0.59 to 0.70) to 
a postoperative mean of 1.07 (95% CI, 0.98 to 1.16). 
By comparison, patients with diffuse or lower lobe 
disease experienced a 38% improvement in FEV 1 
(preoperative mean = 0.70 [95% CI, 0.63 to 0.78]; 
postoperative mean = 0.93 [95% CI, 0.85 to 1.01]). 
In contrast, however, there was no significant differ- 
ence in the change in dyspnea scale for the three 
patterns (p = 0.34) (Table I). 
Age, To investigate the association between age 
and clinical outcome, we compared change in FEV 1 
among age-specific groups using one-way ANOVA. 
Patients aged 70 years or older experienced signifi- 
cantly less improvement than did patients younger 
than 70 for all measures of change in FEV 1 (Table 
II). Patients aged 70 years or older experienced a 
48% improvement in the FEV 1 (preoperative FEV 1 
mean of 0.69 L [95% CI, 0.61 to 0.76 L] and 
postoperative FEV 1 mean of 0.97 L [95% CI, 0.87 to 
1.06 L]) compared with an increase of 76% in 
younger patients (from a preoperative FEV 1 mean 
of 0.64 [95% CI, 0.58 to 0.70] to a postoperative 
mean of 1.08 [95% CI, 0.98 to 1.18]). Although older 
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Table II. Relationship between age and clinical outcomes 
AFEV1 (L ) % AFEV1 A %Pred Mkyspnea 
Age Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) 
<70 yr 0.44 (0.36, 0.52) 76.16 (63.55, 88.76) 16.65 (14.00, 19.30) 1.84 (1.57, 6.27) 
-->70 yr 0.28 (0.23, 0.34) 47.64 (38.96, 56.33) 11.92 (9.58, 14.27) 1.47 (1.15, 1.78) 
Significance* p = 0.014 p = 0.0004 p = 0.01 p = 0.08 
2WEV vChange from baseline FEV1 in liters; %AFEV1, percent change from baseline FEV~ in liters; Lx%Pred, change from baseline percent predicted FEV G 
2d3yspnea, change in dyspnea score. 
*t Test for difference between two means. 
patients experienced a smaller change in the mean 
dyspnea score, 1.47 (95% CI, 1.15 to 1.78) in older 
patients compared with 1.84 (95% CI, 1.57 to 6.27) 
for younger patients), the difference was not statis- 
tically significant (p = 0.08). 
When the effects of the emphysema pattern and 
age were examined simultaneously in a two-way 
ANOVA model, the effect of emphysema pattern 
retained statistical significance for all end points. A 
Significant independent age effect was observed only 
for the comparison with FEV1 percent change from 
baseline used as the outcome. For other outcome 
variables, there was no longer a significant differ- 
ence in clinical outcome between older and younger 
patients after adjusting for roentgenographic em- 
physema pattern (Table III). 
There were no deaths among the 16 patients 75 
years of age or older (range 75 to 81 years) who 
underwent LVRS. They experienced a 54% im- 
provement in the FEV1 from a preoperative mean 
FEV 1 of 0.63 L to a mean postoperative FEV 1 of 
0.97 L. Three (18.75%) patients experienced no 
improvement in their dyspnea , and one (6.25%) 
patient improved one dyspnea grade. The other nine 
patients (56%) showed very substantial c inical im- 
provement with at least a two-grade improvement in 
dyspnea scale. The mean improvement in the dys- 
pnea score was 1.36 _+ 1.28 for patients 75 years of 
age or older. 
Prednisone use. There were no significant differ- 
ences in FEV 1 change associated with preoperative 
prednisone dose (see the appendix). Although 
ANOVA showed a significant difference in dyspnea 
change associated with different doses of pred- 
nisone, there was no significant trend in dyspnea 
change with increasing dose. 
Dyspnea change was greatest for patients whose 
preoperative prednisone dose was 6 to 10 mg and 
lowest for patients with a preoperative dose greater 
than 10 mg. Patients receiving more than 10 mg of 
prednisone before the operation included three at a 
dose of 15 mg, one receiving 17.5 rag, eight receiving 
20 mg, and one patient receiving a preoperative 
dose of 40 mg. Their FEV 1 increased 62% from a 
preoperative mean of 0.66 (95% CI, 0.49 to 0.83) to 
a postoperative mean of 1.00 (95% CI, 0.75 to 1.25). 
By comparison, patients whose preoperative pred- 
nisone dose was 10 mg or less experienced an 
increase in FEV~ of 66% (preoperative mean of 0.66 
[95% CI, 0.61 to 0.71]; postoperative mean of 1.05 
[95% CI, 0.97 to 1.13]). Dyspnea grade decreased by 
1.06 (95% CI, 0.27 to 1.86) for patients receiving 
more than 10 mg of prednisone compared with a 
decrease in grade of 1.72 (95% CI, 1.48 to 1.97) in 
patients receiving 10 mg or less. 
For patients receiving at least 20 mg of pred- 
nisone per day, the length of stay averaged 10.4 + 
1.7 days, compared with the 9.4 day mean length of 
stay for the entire series. 
Severe hypoxemia. ANOVA models showed no 
association between preoperative room air blood 
gas Pao z and postoperative change in FEV 1 or 
dyspnea score (see the appendix). 
Preoperatively, 18patients had a mean room air 
blood gas Pao 2 of less than 50 mm Hg, that is, 46.00 
mm Hg (95% CI, 44.52 to 47.48 mm Hg), range 40 
to 50 mm Hg. For these patients, mean Pao2 levels 
increased 16.1 mm Hg after the operation to 62.1 
mm Hg (95% CI, 53.22 to 70.96 mm Hg). Preoper- 
ative mean FEV 1 increased by 91% from a baseline 
of 0.61 (95% CI, 0.43 to 0.79) to a postoperative 
mean of 1.16 (95% CI, 0.82 to 1.51). Three (16.7%) 
of these patients experienced no increase in FEV 1. 
In the overall series, 68% of patients receiving 
oxygen before the operation were weaned from 
oxygen supplementation completely after the proce- 
dure. In contrast, only four (22%) of the 18 patients 
with preoperative Pao 2 less than 50 mm Hg were 
successfully weaned from supplementary oxygen. 
Supplemental oxygen use. The results for all sub- 
sets of patients using less than 4 L of supplemental 
oxygen before the operation were indistinguishable 
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Table Ill. Relationship between age and x-ray pattern of emphysema with clinical outcomes 
zXFEV 1 (L ) % AFEV 1 A % Pred kDyspnea 
Age Pattern Mean (95% (21) Mean (95% CI) Mean (95% CI) Mean (95% CI) 
<70 yr Upper 0.50 (0.41, 0.59) 85.75 (71.75, 99.75) 18.90 (15.93, 21.86) 1.79 (1.50, 2.09) 
<70 yr Low/diff 0.24 (0.13, 0.35) 42.30 (19.66, 64.93) 8.73 (4.56, 12.89) 2.04 (1.40, 2.68) 
>-70 yr Upper 0.31 (0.25, (0.37) 52.79 (43.25, 62.32) 13.19 (10.73, 15.65) 1.42 (1.06, 1.77) 
>-70 yr Low/diff 0.20 (0.07, 0.33) 31.79 (14.17, 49.41) 8.00 (2.52, 13.49) 1.67 (0.94, 2.40) 
Age, Greater or less than 70 years; Pattern, location of the areas of emphysema t rgeted for resection; Upper, upper lobe areas of emphysema t rgeted for 
resection; Low~cliff, lower or diffuse areas of emphysema t rgeted for resection; z~El/), change from baseline FEV1 in liters; %AFEV1, percent change from 
baseline FEV1 in liters; A%Pred, change from baseline percent predicted FEV1; ADyspnea, change in dyspnea score. 
from each other, but the outcomes were significantly 
worse for patients using 4 L of supplemental oxygen 
before the operation. 
Preoperatively, eight patients required 4 L of 
continuous supplemental nasal oxygen. Despite a 
60% increase in the FEV 1 from the mean preop- 
erative level of 0.55 L to the postoperative level of 
0.89 L for these eight patients, four (50%) pa- 
tients had no change in their dyspnea scale and 
four (50%) improved one grade. For patients 
using less than 4 L of supplemental oxygen in the 
perioperative period, the mean improvement in
the dyspnea scale was 1.68, compared with only 
0.5 for patients using 4 L of supplemental oxygen. 
All patients requiring 4 L of supplemental oxygen 
before the operation continued to use supplemen- 
tal oxygen after the operation, compared with a 
68% chance of oxygen independence for all pa- 
tients in the series who required oxygen supple- 
mentation in the preoperative period. 
Hypercarbia. There was no association between 
room air Paco2 and any of the outcome variables 
measured as changes in FEV 1 or dyspnea score (see 
the appendix). 
Preoperatively, 10patients had a room air blood 
gas that showed levels of Paco 2 greater than 55 mm 
Hg (mean of 58.8 [95% CI, 56.3 to 61.3]). The 
postoperative room air blood gas showed a mean 
Paco 2 of 42.1 mm Hg. 
Their preoperative mean FEV 1 increased by 71% 
after LVRS from 0.48 L (95% CI, 0.38 to 0.58) to a 
postoperative mean of 0.81 L (95% CI, 0.55 to 1.07), 
compared with a 62% change in patients with pre- 
operative Paco 2 less than 55 mm Hg from preoper- 
ative mean FEV 1 of 0.67 L (95 5 CI, 0.62 to 0.71 L) 
to a postoperative mean FEVa of 1.04 L (95% CI, 
0.97 to 1.12 L). In patients with preoperative Paco 2 
greater than 55 mm Hg, dyspnea score decreased by 
a mean of 1.4 (95% CI, 0.64 to 2.11) compared with 
a decrease of 1.7 (95% CI, 1.48 to 1.92) in patients 
with a lower preoperative Paco 2. 
Diaphragmatic excursion. Twenty-two patients 
had diaphragmatic excursion greater than 3 cm on at 
least one side. The average improvement in FEV 1 
for this group of patients was 0.37 L (95% CI, 0.28 
to 0.46 L) compared with 0.38 L (95% CI, 0.32 to 
0.44 L) for patients with diaphragmatic excursion 
less than or equal to 3 cm (t test for difference 
between groups, p = 0.21). 
Pulmonary function test criteria. There was no 
difference in outcome measured as change in FEV~ 
(F = 0.71, p = 0.49), change in FEV1 percent 
predicted (F = 0.36,p = 0.70), or change in dyspnea 
score (F = 0.05, p = 0.95), when they were com- 
pared by preoperative l vel of FEV 1 by means of 
one-way ANOVA (see the appendix). 
For 55 patients with a preoperative FEV1 less 
than 0.5 L, the mean length of stay in the hospital 
was 11.1 days and there were five deaths (9%). This 
subgroup of patients experienced an 87% improve- 
ment in FEV~, preoperative mean of 0.39 (95% CI, 
0.37 to 0.41) to a postoperative mean FEV 1 of 0.73 
(95% CI, 0.67 to 0.78), compared with 56% im- 
provement from baseline in patients with FEV 1 
greater than 0.5 L, preoperative mean of 0.76 (95% 
CI, 0.71 to 0.81) to a postoperative mean of 1.16 
(95% CI, 1.07 to 1.24). The dyspnea score decreased 
by 1.71 (95% CI, 1.36 to 2.05) for patients with 
FEV 1 less than 0.5 L compared with 1.67 (95% CI, 
1.41 to 1.93) for patients with an FEV 1 greater than 
0.5 L (p = 0.63). 
Appendix Fig. 1 shows the scattergrams compar- 
ing the preoperative plethysmographic criteria with 
the postoperative change in FEV v Appendix Table 
I shows the lack of association between the ptethys- 
mographic riteria and the percent change from 
baseline FEV 1 after bilateral staple LVRS. 
Discussion 
Early reports of LVRS suggest that the optimal 
operation is a bilateral staple operation that im- 
proves the FEV 1 between 55% and 98%. 1-9 A1- 
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Table IV. Summary of selection criteria by history for LVRS at multiple centers' (listed by reference number) 
Reference number 
1,2 3 4 5 6,7 8 9,10 25 
Age <75 <85 <70 >75 No <75 <80 - -  
Amb.  Yes No Yes Yes Yes Yes Yes - -  
Vent  Yes - -  Yes Yes Yes Yes Yes Yes 
Pred <10 - -  <15 <20 <20 High dose <20 - -  
0 2 <6 L - -  <6  L . . . . .  
Smoke free 6 mo 6 mo 1 yr 6 mo 6 mo 6 mo 6 mo - -  
Rehab Yes No Yes Yes No Yes No Yes 
PAS <45 - -  <45 . . . . .  
PAM <35 - -  <35 - -  - -  <35 - -  - -  
Arnb, Requirement for a patient o be ambulatory; Vent, patient supported by a ventilator; O:~ preoperative oxygen requirement; Smoke free, requirement 
for smoke-free status; Rehab, successful completion of a rehabilitation with a requirement for 30 minutes on a treadmill; PAS, pulmonary artery systolic 
pressure; PAM, pulmonary artery mean pressure. 
though there are as many as 2 million Americans 
who have emphysema, some of these persons are 
not candidates for LVRS. A key issue for LVRS is 
the proper selection of patients. 
The most important concept of patient selection 
for LVRS is to identify patients with hyperexpanded 
lungs with areas of lung tissue that have little to no 
pulmonary function. The basic concept of the oper- 
ation is to resect hese nonfunctional reas to allow 
improved function by the remaining areas with less 
emphysematous change. Therefore the first and 
foremost selection factor has been the presence of a 
heterogeneous pattern of emphysema. In this series, 
the lack of this pattern was the most common 
contraindication for the operation. This review was 
undertaken in an effort to further refine the selec- 
tion criteria for LVRS in patients with a heteroge- 
neous pattern of emphysema. 
Tables IV and V show the various selection 
criteria reported by eight different centers, l-I°' 25 
Because there is little information in these papers to 
support these selection criteria, we reviewed our 
series to evaluate the validity of these patient selec- 
tion criteria. 
A reasonable justification for patient selection is a 
life expectancy long enough to justify the procedure. 
All centers except one noted that patients were 
excluded if they had significant coronary artery 
disease, any severe medical illness, or cancer other 
than prostate cancer. 
There was general agreement that there should be 
an upper limit to age, although the limit varied from 
70 to 85 years. 3' 4 In the present series, there were no 
deaths in 17 patients over 75 years of age. Clinically, 
both FEV 1 and the dyspnea scale improved signifi- 
cantly. Therefore no absolute upper age limit could 
be identified from our data. Patients over 70 years of 
age showed significant clinical improvement, although 
this was not as large an improvement as that achieved 
by patients less than 70 years of age (p = 0.0004). 
Patients requiring 4 L of oxygen before the oper- 
ation showed little or no relief of dyspnea and no 
oxygen independence; thus this does appear to be a 
very strong contraindication to LVRS. 
Six centers included a psychologic assessment 
as part of the preoperative valuation. Miller, 
Lee, and Mansour 4 stated that "panic attacks 
postoperatively were the most significant factor 
leading to postoperative complications and poor 
outcome." Because this has also been our clinical 
impression, all members of our team, including 
the physicians, nurses, the rehabilitation team, 
and respiratory therapists, assess potential candi- 
dates for severe anxiety or depression. In an 
attempt to identify anxiety and depression, pa- 
tients are now routinely tested with the Beck 
anxiety and depression indices. Our pilot study 
suggests that these tools do identify patients at 
risk for a poor postoperative course. 
Pulmonary artery pressures are criteria for selec- 
tion at three centers. This may be reasonable, but 
there are no published ata to support hese criteria, 
and we have no data to support hese criteria. 
There is general agreement that patients hould 
have hyperexpanded lungs with a flattened dia- 
phragm. Cooper and associates 1 have used dia- 
phragm motion less than 3 cm as a criterion. The 
data in the present study do not support diaphrag- 
matic excursion as a selection criterion. 
Plethysmographic criteria logically should help to 
select patients for LVRS, and various criteria have 
been proposed (Table V). Conventional wisdom is 
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Table V. Radiologic and pulmonary function selection criteria for LVRS for multiple centers (listed by 
reference number) 
Reference number 
1,2 3 4 5 6,7 8 9,10 25 
Flat diaph Yes  - -  Yes  Yes  Yes  Yes  Yes  Yes  
Hetero  CT  Yes Yes  Yes  Yes  Yes  Yes  Yes  Yes  
FEV 1 >15% <40% <30% <35% <35% <35% <35% <40% 
<35% 
TLC > 125 % . . . . . .  > 120% 
RV >250% . . . .  >200% - -  - -  
PO 2 - -  >40 >40 >40 - -  >45 >40 - -  
Pco2 <55 <60 <55 <50 <50 <55 <55 <50 
DLCO - -  ? - -  - -  >25% - -  - -  <50% 
Flat diaph, flat diaphragm on chest x-ray film; Hetero CT, heterogeneous pattern of emphysema seen on chest CT scan. 
that patients for LVRS should have hyperexpanded 
lungs; however, the data in this study fail to identify 
absolute plethysmographic criteria for patient selec- 
tion. This does not mean, however, that patients 
with restrictive disease should undergo LVRS, be- 
cause only one patient in the series had a total lung 
capacity less than 100% predicted. This patient's 
chest x-ray film showed hyperexpanded lungs de- 
spite the plethysmographic data. She achieved ex- 
cellent improvement after the operation. 
DLCO has been proposed as a criterion for 
LVRS 7. 25 The data in this study again fail to demon- 
strate an association with clinical outcomes. Gelb 
showed a lack of association between DLCO and 
FEV 1 when the FEV 1 was less than 1 L. 13 Because the 
FEV 1 is less than 1 L in essentially all patients for 
LVRS, the DLCO would not be expected to show any 
association with the degree of emphysema. 
Our data show no significant associations be- 
tween the preoperative phlethysmographic data 
and the postoperative change in the FEV~. It was 
interesting to note that the mean change in the 
FEV 1 was the same (390 ml), irrespective of the 
preoperative FEV 1. We believe that the absolute 
change in FEV1 should be used for an analysis of 
this kind because the same absolute change in the 
FEV 1 (390 ml) represents an artificially higher 
percent change of a low preoperative FEV 1 (78% 
of 0.5 L) compared with a higher preoperative 
FEV 1 (39% of 1.0 L). 
The most significant factor that could be iden- 
tified was the presence of bilateral upper lobe 
pattern of emphysema. The Washington Univer- 
sity group also found this to be a very important 
selection factor. 1' 3 Patients with only a mild de- 
gree of heterogeneity averaged less improvement 
than patients with a high degree of heterogeneity 
(mean increase in FEV1 < 350 ml vs 500 ml, 
respectively).3, 25 
To evaluate the role of emphysema versus small 
airways disease in chronic obstructive pulmonary 
disease, Gelb and associates 26 evaluated 116 consec- 
utively seen outpatients with fixed expiratory airway 
limitation. Thin-cut high-resolution CT scans dem- 
onstrated severe mphysematous change (anatomic 
destruction graded as > 60) in only 30%. This 
suggests that LVRS can help only a minority of 
patients who clinically have emphysema. 
Surgical series have reported that 18% to 24% 
of patients creened were deemed candidates for 
LVRS. 2'8 In this series, 31% of the screened 
patients were accepted because some pulmonolo- 
gists who regularly refer patients to our center 
prescreen their patients o that almost all of the 
patients that they refer are good candidates for 
the procedure. 
In conclusion, in this series of patients undergoing 
LVRS, the presence of a bilateral upper lobe hetero- 
geneous pattern of emphysema on chest CT and lung 
perfusion scan is strongly associated with improved 
clinical outcome. Patients who require 4 L of nasal 
oxygen are not good candidates for LVRS. Although 
patients over 70 years of age do experience a signifi- 
cant improvement in clinical status, they experienced 
less improvement than younger patients. After pa- 
tients have been selected for the presence of a heter- 
ogeneous pattern of emphysema, clinical factors and 
physiology are not significantly associated with clinical 
outcome. Thus our results do not support further 
refinement ofpatient selection criteria for LVRS after 
patients have been chosen for the presence of a 
heterogeneous pattern of emphysema. These results 
do not support he arbitrary patient selection criteria 
that are reported in the literature. 
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Discuss ion 
Dr. Marvin Pomerantz (Denver, Colo.). I congratulate 
Dr. McKenna for his leadership role in using bilateral 
video-assisted thoracic surgery to perform LVRS in ap- 
propriate patients with emphysema. Our own experience 
has been limited to bilateral LVRS using the transsternal 
approach. We would agree that the most important pre- 
operative factor is the heterogeneous pattern of emphy- 
sema with so-called target areas, particularly those lacking 
perfusion to the upper lung zones. However, we achieved 
one of our best successes in a patient with cq-antitrypsin 
disease who required 4 L of supplemental oxygen. She was 
on our transplant list and could not walk across the room. 
She had marked emphysematous changes in both lower 
lobes. We did a right lower lobectomy and resected the 
basilar segments on the left lower lobe. She now exercises 
without supplemental oxygen and, in fact, does not use 
supplemental oxygen at all. We have noted in our patients 
that the peak oxygen consumption at peak work increased 
after the operation. This appears to correlate with in- 
creases in FEV 1 but not with decreases in lung volumes. 
My first question to Dr. McKenna relates to this finding. 
Have you noted the same in your series? 
Dr. MeKenna. The optimal tool to use to evaluate 
patients after the operation is unknown. As you indicate, 
the postoperative courses do not always correlate with the 
FEV 1. We found patients with dramatic improvements in
their clinical abilities, but no changes in the FEV 1. The 
things that we have noticed that correlate the best with 
outcomes and with what really happens with this opera- 
tion are the changes in elastic recoil and also the changes 
in residual volumes. Patients are breathing much farther 
away from their total lung capacity, and that makes their 
sense of dyspnea much decreased. 
Dr. Pomerantz. My second question relates to the Pao 2 
and Paco a. In our patients it seems that the Pco 2 de- 
creases more consistently with rest and exercise after the 
operation than the Po z increases. Did you have the same 
experience in this situation? 
Dr. McKenna. Yes. The results of the Pco2 dramatically 
decreased but that did not necessarily correlate with 
improvement clinically in the patients, and the changes in 
the room air Po 2 have been variable. 
Dr. Pomerantz. My last question relates to rehabilita- 
tion. Dr. Cooper emphasizes the importance of a 6- to 
8-week pulmonary rehabilitation before the operation. In 
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your paper there was no mention of rehabilitation. Do you 
use rehabilitation? If not, why not? 
Dr. MeKenna. A significant number of our patients 
have not had rehabilitation ahead of time. I think that 
practice is appropriate in properly selected patients. Re- 
habilitation is a helpful patient selection criteria. It shows 
that the patients can control their anxiety, can control 
their depression, and can accomplish the work that they 
need to accomplish to get benefit from the operation. 
However, I think the operation can be done without 
rehabilitation i properly selected patients. 
Dr. Pomerantz. Finally, I would caution those investi- 
gators who are either just beginning their program to try 
not to take the outliers that Dr. McKenna presented so 
well. We may not all have as much expertise as he does. 
Patients with very low FEV 1 and those with low Po 2 and 
high Pc02 will often not do well. 
Dr. Joseph Bavaria (Philadelphia, Pa.). At the Univer- 
sity of Pennsylvania we have done approximately 150 of 
these operations, and about half of them have been 
through a mediastinotomy and the other half have been 
through the video-assisted thoracic approach. I would like 
for you to comment on the 11% mortality rate in patients 
with low FEV 1. We have also noted this early in our 
experience. Recently there have been basically two types 
of referral patterns: about 75% of the patients come in 
directly through the thoracic surgeon's office and the 
other 25% actually come in through the lung transplant 
format. These patients all have an FEV 1 of less than 19%. 
We have found that with patients with an FEV 1 of less 
than or equal to 19% a bilateral procedure, whether 
through a mediastinotomy or through a video-assisted 
thoracic approach, is not appropriate. Instead, we have 
now gone to a bilateral sequential approach--two unilat- 
eral approaches in sequence, and our mortality rate is 0% 
in patients with an FEV 1 of less than 19 percent. Would 
you please comment on that? We believe that these 
patients do not tolerate bilateral manipulation of the lung 
at the same time very well. 
Dr. McKenna. At the 1996 Annual Meeting of The 
American Association for Thoracic Surgery, we presented 
a study comparing unilateral and bilateral approaches. We 
found no difference in our operative morbidity or mortal- 
ity for the unilateral and bilateral approach in patients 
who had a severely depressed Po2 or a severely decreased 
FEV~. The one important factor that we noted, however, 
was a very significantly increased i-year mortality rate for 
patients who had a very low FEV1 if they had a unilateral 
operation. My belief is that patients who are severely 
compromised need to have the best improvement possi- 
ble, and that is achieved with a bilateral staple operation. 
We were able to do that without any increased risk 
compared with a unilateral approach. 
Dr. Bavaria, Our approach is also to do a bilateral oper- 
ation but just to do it sequentially--tactics versus trategics. 
My second question concerns oxygen. We found that 
almost none of our patients who had a low DLCO on their 
pulmonary function testing were able to dispense with sup- 
plemental oxygen. Did you see that in your series as well? 
Dr. MeKenna. The DLCO correlates very poorly with 
the presence of emphysema in patients who have an FEV~ 
less than 1 L. That has been reported by one of the 
pulmonologists who works with me. The correlation be- 
tween DLCO and postoperative r sults was poor, and I 
did not find that to be predictive. 
Dr. Bavaria. Last, do you have any recommendations 
regarding the ongoing Medicare issues? 
Dr. MeKenna. Can I have the rest of the day to answer 
that question? I do not see any way to fight city hall. We 
need to participate in that trial, get it up and running as 
fast as possible, and get the data to them so that the 
overwhelming difference between LVRS and rehabilita- 
tion is apparent. 
Dr, John Benfield (Sacramento, Calif.). I want to thank 
Dr. Marvin Pomerantz for his leading role in helping to 
establish some guidelines with regard to this new proce- 
dure. Thoracic surgery and allied specialties are indebted 
to him for effective work. 
There is now an investigational therapeutic protocol 
that has been advanced by the National Institutes of 
Health (NIH) in cooperation with the Health Care Fi- 
nance Agency (HCFA). To my knowledge, this is the very 
first time that a new approach as been subjected to a 
prospective study. Within a relatively short period of time 
it should answer some of the questions that are still 
pending. We are pushing very hard for a rapid accrual to 
this protocol so that the unresolved questions will in fact 
become resolved. Again, to my knowledge this is the first 
time that HCFA and the NIH have come together, and I 
think this is an important example of leadership by 
thoracic surgery and allied medical specialties and coop- 
eration with HCFA and NIH toward the best available 
patient care. 
Dr. Arthur Thomas (San Francisco, Calif.). This is 
obviously a palliative procedure for a condition that in 
some patients is self-induced. In the days of cost effective- 
ness this comes into play. Obviously most if the patients 
still require supplemental oxygen after the procedure. 
How much better are they able to function? 
You did not mention longevity. Do they really live 
longer or do they just have a prolonged better experience 
for the short duration? Second, do you have any manda- 
tory selection criteria, such as not smoking anymore? 
Dr. MeKenna. Smoking cessation is an absolute re- 
quirement o have the operation. Patients must have 
stopped smoking at least 6 months before the procedure. 
That is usually not a problem. Most of these patients are 
in such bad condition that they are no longer able to draw 
on a cigarette. 
You mentioned oxygen. Seventy percent of our patients 
after a bilateral Staple operation are not using supplemental 
oxygen. Functionally, the patients whose condition improves 
are dramatically better with this operation. Unfortunately, 
some note no improvement, and LVRS is not without 
operative morbidity and mortality. However, in the majority 
of patients the quality of life is very substantially improved. 
I do not have sufficient data to address the question of 
longevity. The average improvement in the FEV 1 in these 
patients is 400 ml. These patients tend to lose about 50 ml 
per year in their FEV1, so that we would hope that they 
would get at least 5 years of benefit from the operation: 
This is certainly a palli~itive operation. 
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Appendix Fig. 1. Scattergrams comparing the postoperative change in the FEV1 with the preoperative 
FEV1 (A), preoperative forced vital capacity (FVC) (B), preoperative residual volume (RV) (C), 
preoperative total lung capacity (TLC) (D), preoperative DLCO (E), and preoperative Pao 2 (F). 
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Appendix Table I. Relationship between pulmonary function tests, arterial blood gases, and the use of 
prednisone with the clinical outcome :~ 
AFE V 1 % 2~F'EV 1 A % Pred 2ff)yspnea 
Variable Mean (95% CI) Mean (95% C1) Mean (95% CI) Mean (95% CI) 
FEV1 
<0.5 L 0.33 (0.28, 0.39) 86.90 (73.15, 100.68) 14.30 (12.10, 16.50) 
0.5-0.75 L 0.41 (0.32, 0.50) 66.37 (51.89, 80.85) 15.76 (12.54, 19.00) 
>0.75 L 0.38 (0.29, 0.49) 41.94 (28.49, 55.39) 13.95 (9.92, 17.98) 
Significance* p = 0.49 p = 0.0004 p = 0.70 
RV 
-<150% 0.39 (0.26, 0.52) 70.90 (42.60, 99.20) 15.71 (10.44, 20.98) 
151-180% 0.42 (0.29, 0.56) 70.87 (51.27, 90.47) 16.84 (12.28, 21.40) 
181-205% 0.32 (0.24, 0.40) 62.20 (45.50, 78.91) 13.31 (9.93, 16.69) 
206-230% 0.33 (0.24, 0.42) 46.09 (34.48, 57.70) 12.84 (9.35, 16.33) 
>230% 0.41 (0.28, 0.54) 74.03 (53.08, 94.99) 14.78 (10.22, 19.34) 
Significance* p = 0.66 p = 0.24 p = 0.67 
TLC 
-<100% 0.35 (0.21, 0.49) 71.84 (41.78, 101.91) 15.19 (9.41, 20.96) 
101-110% 0.46 (0.27, 0.65) 88.43 (60.61, 116.26) 17.25 (10.87, 23.62) 
111-120% 0.35 (0.24, 0.46) 46.86 (33.62, 60.11) 13.12 (9.32, 17.04) 
121-130% 0.33 (0.23, 0.42) 55.18 (37.96, 72.40) 13.49 (9.40, 17.59) 
131-140% 0.43 (0.31, 0.54) 69.09 (51.47, 86.72) 16.42 (12.42, 20.42) 
>140% 0.35 (0.22, 0.49) 57.44 (34.43, 80.44) 13.13 (8.25, 18.01) 
Significance* p = 0.68 p = 0.13 p = 0.74 
Pao2 
-<55 mm Hg 0.42 (0.31, 0.58) 78.23 (59.51, 96.96) 16.91 (12.68, 21.14) 
55-60 mm Hg 0.32 (0.19, 0.45) 58.35 (38.25, 78.46) 12.43 (7.85, 17.00) 
61-65 mm Hg 0.38 (0.28, 0.48) 71.09 (51.38, 90,80) 14.81 (10.74, 18.87) 
66-75 mm Hg 0.35 (0.26, 0.44) 55.50 (39.75, 79.17) 14.23 (10.45, 18.01) 
>75 mm Hg 0.35 (0.23, 0.47) 55.87 (35.23, 76,50) 13.73 (9.59, 17.88) 
Significance* p = 0.67 p = 0.35 p = 0.71 
Paco 2 
-<35 mm Hg 0.38 (0.24, 0.53) 47.23 (28.15, 66.32) 14.64 (8.46, 20.82) 
36-40 mm Hg 0.41 (0.33, 0.49) 64.26 (50.71, 77.80) 15.55 (12.51, 18.59) 
41-45 mm Hg 0.38 (0.28, 0.48) 66.82 (49.90, 83.74) 14.86 (11.22, 18.49 
46-55 mm Hg 0.28 (0.19, 0.38) 60.39 (41.68, 79.09) 11.99 (8.20, 15.70) 
>55 mm Hg 0.33 (0.12, 0.54) 71.16 (29.54, 112.77) 13.48 (6.92, 20.05) 
Significance* p = 0.56 p = 0.70 p = 0.79 
Pred. 
0 0.36 (0.30, 0.43) 61.32 (49.89, 72.76) 14.21 (11.90, 16.52 
1-5 mg 0.35 (0.23, 0.48) 61.02 (43.48, 78.55) 14.64 (9.63, 19.65) 
6-10 mg 0.48 (0.32, 0.65) 80.67 (56.67, 104.67) 18.32 (12.81, 23.83 
>10 mg 0.34 (0.16, 0.51) 61.52 (27.39, 95.65) 12.67 (6.98, 18.36) 
Significance* p = 0.34 p = 0.34 p = 0.34 
1.71 (1.36, 2.05) 
1.70 (1.39, 2.00) 
1.63 (1.16, 2.09) 
p = 0.95 
2.21 (1.77, 2.65) 
1.65 (1.25, 2.06) 
1.86 (1.44, 2.28) 
1.78 (1.15, 2.40) 
1.39 (0.99, 1.79) 
p = 0.27 
2.05 (1.36, 2.73) 
1.79 (1.24, 2.34) 
1.33 (0.78, 1.88) 
1.87 (1.44, 2.29) 
1.78 (1.24, 2.32) 
1.53 (1.02, 2.04) 
p = 0.53 
1.63 (1.10, 2.15) 
1.29 (0.80, 1.79) 
1.83 (1.35, 2.41) 
1.76 (1.40, 2.12) 
1.75 (1.26, 2.24) 
p = 0.56 
1.32 (0.86, 1.78) 
1.71 (1.30, 2.12) 
1.85 (1.44, 2.26) 
1.66 (l.26, 2.06) 
1.38 (0.64, 2.11) 
p = 0.62 
1.60 (1.28, 1.91) 
1.31 (0.85, 1.78) 
2.14 (1.74, 2.53) 
1.06 (0.35, 1.76) 
p = 0.03 
Pred., Preoperative dose of prednisone; kFEV1, change from baseline FEV 1 in liters; %AFEV1, percent change from baseline FEV1 in liters; A% Pred, change 
from baseline percent predicted FEV1; kDyspnea, change in dyspnea score. 
